Objective To explore the curative effect of bisoprolol combined with atorvastatin on patients with stable angina pectoris（SAP）. Methods The clinical data of 448 SAP patients admitted to our hospital from January 2018 to December 2020 were collected retrospectively. According to different treatment schemes

224 patients were treated with atorvastatin as control group and 224 patients were treated with bisoprolol combined with atorvastatin as observation group. The efficacy

frequency and duration of angina pectoris

heart function [left ventricular ejection fraction（LVEF）

left ventricular end-diastolic diameter（LVEDD）

left ventricular end-systolic diameter（LVESD）]

brachial artery blood flow-mediated endothelial diastolic function（FMD）

granular membrane protein-140（GMP140） and the incidence of adverse reactions were compared between the two groups before and after treatment. Results The total effective rate of the observation group was 93.30% higher than that of the control group（78.13%

p <0.05）. After treatment

the frequency and duration of angina pectoris in observation group were lower than those in control group（p<0.05）. After treatment

LVEF in observation group was higher than that in control group

and LVESD and LVEDD were lower than those in control group（p <0.05）. After treatment

FMD and GMP140 in observation group were higher than those in control group（p<0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（p >0.05）. Conclusions Bisoprolol combined with atorvastatin is effective in the treatment of SAP patients

which can effectively control angina pectoris

improve heart function and inhibit the progression of atherosclerosis

and has high safety.